Welcome to our dedicated page for Sartorius Pfd news (Ticker: SUVPF), a resource for investors and traders seeking the latest updates and insights on Sartorius Pfd stock.
SARTORIUS AG PFD W/O (SUVPF) relates to preferred shares of Sartorius AG, a life science group that regularly publishes news about its activities in biopharmaceutical research and manufacturing. The company’s communications highlight developments in its Lab Products & Services and Bioprocess Solutions divisions, as well as updates on capacity expansions, acquisitions, and sustainability initiatives that affect its global operations.
News about Sartorius often covers bioprocessing technologies, including single-use solutions for manufacturing biotech drugs, vaccines, and cell and gene therapies. Company releases describe investments in new production sites and hubs, such as facilities in South Korea, North America, and China, which are intended to bring manufacturing and service capabilities closer to key biopharma markets. These updates provide context on how Sartorius is expanding its footprint and responding to demand in the life science and biopharmaceutical sectors.
Another recurring theme in Sartorius news is portfolio development through acquisitions and product innovation. The company reports on acquisitions of complementary businesses, such as cell culture media specialists, and on enhancements to its laboratory and bioprocess offerings. Recent communications also emphasize sustainability-related news, including the use of ISCC Plus-certified renewable raw materials in selected products to reduce reliance on fossil-based plastics in bioprocessing applications.
Investors and observers following SUVPF-related news can expect updates on Sartorius’ financial performance, divisional growth, capacity expansion projects, and initiatives in areas like sustainability and bioanalytics. This news flow offers insight into how the company positions itself within the life science and biopharmaceutical landscape and how its strategic decisions may influence its long-term development.
Sartorius (OTC:SARTF) sharpened medium-term climate targets and received validation from the Science Based Targets initiative on February 16, 2026. The company set a 42% reduction in Scope 1 and 2 CO₂e by 2030 versus 2022 and a 51.6% Scope 3 intensity reduction by 2030 versus 2022.
Long-term ambition remains a climate-neutral value chain and net-zero by 2045. The updated targets cover more than 95% of emission sources and are integrated into Executive Board long-term remuneration.
Sartorius (OTC: SUVPF) expanded its ISCC Plus certified production network on January 14, 2026, adding Göttingen, Germany and M'Hamdia, Tunisia to earlier-certified sites in Aubagne, France and Stonehouse, UK.
The company will produce the PFAS-free Sartopore Evo filter in Göttingen and selected Flexsafe bags in M'Hamdia using certified renewable or second-generation feedstock, lowering fossil-based content by about 70% in Flexsafe film and 40–60% in Sartopore Evo filters. Sartorius said it plans to expand certified raw-material use across its global production network.
Sartorius reported a 15.0% increase in sales revenue for 2022, reaching approximately
The Supervisory Board of Sartorius AG has proposed a dividend of 1.26 euros per preference share and 1.25 euros per ordinary share, totaling 85.9 million euros to be distributed. This represents an increase from the previous year's dividends of 0.71 euros and 0.70 euros respectively. The proposal will be discussed at the Annual General Shareholders' Meeting scheduled for March 25, 2022. Additionally, the Board recommended candidates for re-election, including David Raymond Ebsworth and Daniela Favoccia, while nominating Frank Riemensperger for election.
Sartorius closed fiscal 2021 with remarkable growth driven by pandemic-related demand and acquisitions, achieving a sales revenue of approximately 3,449 million euros, a 49.3% increase in constant currencies. Order intake surged 52.3% to 4,268 million euros. Underlying EBITDA rose by 69.7% to 1,175 million euros, with a margin of 34.1%. For 2022, Sartorius anticipates double-digit revenue growth, projecting sales between 14% and 18%, while maintaining a high EBITDA margin. The company emphasizes investments in capacity expansion and CO2 reduction initiatives.
Sartorius is investing approximately 270 million euros (around 300 million USD) to expand its operations in South Korea by 2024. This includes the establishment of cell culture media production and sterile system assembly in Songdo, Incheon. The investment aims to enhance delivery speed and capacity in response to the growing biopharmaceutical industry in the region. Construction will span 25,000 square meters with facilities for manufacturing and logistics, creating around 750 new jobs. Operations are expected to start by the end of 2024.
Sartorius reported strong growth for the nine months ending September 2021, with sales revenue rising by 53.9% to approximately 2,527 million euros. The company benefitted from high demand in biopharmaceutical development and production, alongside contributions from coronavirus vaccine-related activities. Order intake surged by 72.3% to 3,286 million euros. Underlying EBITDA increased by 77.3% to 866 million euros, with a margin of 34.3%. Sartorius also confirmed its optimistic growth forecast for the full year, projecting a 45% increase in sales.
Karin Sartorius-Herbst and LifeScience Holding SCSp (LSH) have entered option agreements to acquire approximately 56.7% of the shares of the Horst Sartorius community of heirs. This acquisition affects 50.09% of the ordinary shares of Sartorius AG. The transaction is subject to common conditions and approvals, expected to close by the end of 2021. Notably, this change in ownership will not impact Sartorius AG's strategic direction or management. The press release includes forward-looking statements with disclaimers regarding potential risks and uncertainties.
Sartorius is expanding its operations in Michigan by opening a new 130,000-square-foot plant in Ann Arbor by late 2023. This facility will consolidate existing operations and serve as a center for Laboratory and Bioprocess Products and Services in North America. The expansion will create 160 jobs over three years and positions Sartorius to meet the increasing demand for biopharmaceutical technologies. Additionally, the company plans to double its capacities for key product groups by 2025, further enhancing its presence in the Ann Arbor biotech hub.
Sartorius has expanded its Application and Service Hub in Zhangjiang Science City, Shanghai, to enhance support for the growing biopharmaceutical market in China. Covering over 3,000 square meters, the facility includes a new Application Center 3.0 and Confidence® Validation Services Laboratory 2.0. This investment, aimed at meeting local demand, introduces innovations in drug discovery and process development. Key features include a doubling of validation capacity and the introduction of new testing capabilities. Sartorius plans to continue expanding its local presence and services, employing over 700 staff in China.